Connect Biopharma Holdings Limited
CNTB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $26 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $1 | $0 |
| Gross Profit | $26 | -$1 | -$1 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $29 | $52 | $95 | $81 |
| G&A Expenses | $19 | $0 | $20 | $19 |
| SG&A Expenses | $19 | $14 | $20 | $19 |
| Sales & Mktg Exp. | $0 | $14 | $0 | $0 |
| Other Operating Expenses | $0 | -$4 | -$1 | -$3 |
| Operating Expenses | $48 | $62 | $115 | $98 |
| Operating Income | -$22 | -$62 | -$118 | -$99 |
| % Margin | -86.2% | – | – | – |
| Other Income/Exp. Net | $7 | $3 | -$0 | -$103 |
| Pre-Tax Income | -$15 | -$59 | -$116 | -$205 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$60 | -$116 | -$205 |
| % Margin | -60% | – | – | – |
| EPS | -0.28 | -1.08 | -14.5 | -25 |
| % Growth | 74.1% | 92.6% | 42% | – |
| EPS Diluted | -0.28 | -1.08 | -14.5 | -25 |
| Weighted Avg Shares Out | 55 | 55 | 55 | 52 |
| Weighted Avg Shares Out Dil | 55 | 55 | 55 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $0 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$22 | -$58 | -$117 | -$202 |
| % Margin | -83.7% | – | – | – |